| Disease | Treatment | Product | ||
|---|---|---|---|---|
| Option 1 | Option 2 | |||
| Age-related macular degeneration(AMD) | DFPP | Rheofilter | Plasmaflo | |
Age-related macular degeneration (AMD)
In the field of ophthalmology, double filtration plasmapheresis (DFPP) is performed for the treatment of dry age-related macular degeneration (AMD). AMD is the leading cause of visual impairment and blindness in people 65 years of age or older in the USA. AMD occurs in two forms: the exudative "wet" form accompanied by choroidal neovascularization; and the nonexudative "dry" form involving drusen, geographic atrophy, etc. The nonexudative form accounts for 80-90% of all AMD cases in the USA.
No effective therapy has been established for maintaining or improving vision in dry AMD. A retinal microcirculatory disorder is suspected to cause dry AMD. Recently, however, several studies have confirmed the effectiveness of DFPP in dry AMD treatment. Clinical evaluation of Asahi Kasei Kuraray Medical products for the treatment of dry AMD is underway in the USA with the aim of the FDA approval.
Plasmaflo, Cascadeflo, Rheofilter, Plasorba, Immusorba, Cellsorba, CUREFLO, and Plasauto are trademarks of Asahi Kasei Kuraray Medical Co., Ltd.